Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $29.84 USD
Change Today -0.06 / -0.20%
Volume 173.1K
CSII On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

cardiovascular systems inc (CSII) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - $41.28
52 Week Low
10/1/14 - $23.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cardiovascular systems inc (CSII) Related Bloomberg News

View More Bloomberg News

cardiovascular systems inc (CSII) Related Businessweek News

No Related Businessweek News Found

cardiovascular systems inc (CSII) Details

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and markets devices for the treatment of vascular diseases. Its products include catheter-based platforms, such as the Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. The company markets its products through direct sales force to hospitals and office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

479 Employees
Last Reported Date: 08/28/14
Founded in 1989

cardiovascular systems inc (CSII) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $330.7K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $305.4K
Chief Healthcare Policy Officer
Total Annual Compensation: $318.7K
Chief Administrative Officer, Compliance Offi...
Total Annual Compensation: $296.4K
Compensation as of Fiscal Year 2014.

cardiovascular systems inc (CSII) Key Developments

Cardiovascular Systems Inc. Completes Enrollment for its Coronary Orbital Atherectomy System Trial (COAST) Study

Cardiovascular Systems Inc. announced that it has completed enrollment for its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in both Japan and the United States, the study is designed to assess the safety and efficacy, as well as economic outcomes, of CSI’s new micro crown Orbital Atherectomy System (OAS) in treating severely calcified coronary lesions in patients suffering from Coronary Artery Disease (CAD). As designed, a total of 100 patients were enrolled in the study. The 1.25 mm micro crown is CSI’s second-generation system designed to facilitate stent delivery in patients with severely calcified lesions who are acceptable candidates for percutaneous transluminal coronary angioplasty (PTCA) or stenting. The micro crown OAS is designed to improve the tracking and piloting of the OAS driveshaft and the ability of the crown to reach the lesion while operating at lower rotational speeds. COAST builds on CSI’s ORBIT II study, the first trial designed to treat patients with severely calcified lesions who are typically excluded from all major trials, but commonly seen in the real world. COAST is a prospective, single-arm, multi-center, global, investigational study. In November 2014, CSI completed the enrollment of 26 patients at five sites in Japan. Seventy-four patients were enrolled in 15 sites in the United States. The study’s principal co-investigators are Dr. Shigeru Saito, Director of Cardiology and Catheterization Laboratories at Shonan Kamakura General Hospital, Kamakura, Japan and Dr. Gregg Stone, Director of the Cardiovascular Research and Education Center for Interventional Vascular Therapy at Columbia University Medical Center, New York.

Cardiovascular Systems, Inc. Receives FDA Clearance

Cardiovascular Systems Inc. announced that it has received FDA clearance for its new ViperWire Advance® Peripheral Guide Wire with Flex Tip for their Peripheral Orbital Atherectomy Systems (OAS). The new guide wire provides physicians with improved flexibility, navigation and ease-of-use 'particularly in hard-to-reach, tortuous vessels' when treating arterial calcium associated with peripheral artery disease (PAD). Building on the success of the current ViperWire Advance, this next-generation wire offers a reduction in tip stiffness, with comparable torque transfer, making it easier for physicians to navigate vasculature. The guide wire also provides improved trackability through tortuous peripheral arteries. Additional features and enhancements of the ViperWire Advance Guide Wire with Flex Tip include: A Nitinol support coil, for a more durable tip and the ability to be reshaped for multiple uses; and Larger proximal core, for improved kink resistance and more delivery support for adjunctive devices. CSI anticipates launching ViperWire Advance with Flex Tip in early August 2015. The guide wire is for use with CSI’s 145 cm Stealth 360® and Diamondback 360® Peripheral OAS.

Cardiovascular Systems Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-11-2015 08:40 AM

Cardiovascular Systems Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-11-2015 08:40 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: David L. Martin, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSII:US $29.84 USD -0.06

CSII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $27.79 USD +1.20
CryoLife Inc $10.95 USD -0.06
Endologix Inc $14.26 USD +0.15
Spectranetics Corp/The $17.10 USD -0.29
Vascular Solutions Inc $37.23 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation CSII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOVASCULAR SYSTEMS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at